413 related articles for article (PubMed ID: 27636993)
1. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study.
Zhang WW; Lin JY; Wang GY; Huang CL; Tang LL; Mao YP; Zhou GQ; Liu LZ; Tian L; Li JB; Ma J; Guo R
Radiother Oncol; 2024 May; 194():110189. PubMed ID: 38432309
[TBL] [Abstract][Full Text] [Related]
4. Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era.
Zhang LN; Gao YH; Lan XW; Tang J; Su Z; Ma J; Deng W; OuYang PY; Xie FY
Oncotarget; 2015 Dec; 6(41):44019-29. PubMed ID: 26528755
[TBL] [Abstract][Full Text] [Related]
5. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
[TBL] [Abstract][Full Text] [Related]
8. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
Luo Y; Qin Y; Lang J
Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
10. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
[TBL] [Abstract][Full Text] [Related]
11. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced nasopharyngeal cancer using low- or high-dose concurrent chemoradiotherapy with intensity-modulated radiotherapy: A propensity score-matched, nationwide, population-based cohort study.
Chen TM; Lin KC; Yuan KS; Chang CL; Chow JM; Wu SY
Radiother Oncol; 2018 Oct; 129(1):23-29. PubMed ID: 29277447
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
[TBL] [Abstract][Full Text] [Related]
16. Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II nasopharyngeal carcinoma after intensity-modulated radiotherapy: A propensity score-matched cohort study.
Wang F; Zhou L; Zhang LJ; Xie CB; Liao ZW; Lin XD; Wen YF
Radiother Oncol; 2024 Feb; 191():110081. PubMed ID: 38185256
[TBL] [Abstract][Full Text] [Related]
17. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma.
OuYang PY; Shi D; Sun R; Zhu YJ; Xiao Y; Zhang LN; Zhang XH; Chen ZY; Lan XW; Tang J; Gao YH; Ma J; Deng W; Xie FY
Oncotarget; 2016 May; 7(22):33408-17. PubMed ID: 27058901
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.
Hua YJ; Han F; Lu LX; Mai HQ; Guo X; Hong MH; Lu TX; Zhao C
Eur J Cancer; 2012 Dec; 48(18):3422-8. PubMed ID: 22835782
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma.
Chen JL; Huang YS; Kuo SH; Hong RL; Ko JY; Lou PJ; Wang CW
Oncotarget; 2017 Feb; 8(8):14068-14077. PubMed ID: 27764778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
